Neutropenia after rituximab treatment: New insights on a late complication

Ofir Wolach, Ofer Shpilberg, Meir Lahav

Research output: Contribution to journalReview articlepeer-review

54 Scopus citations

Abstract

Purpose of Review: Late-onset neutropenia (LON) after rituximab administration may be encountered in various clinical settings. The identification of neutropenia after rituximab treatment may have immediate implications for the clinical management of the patient and on subsequent treatment strategies. Although the pathogenesis of LON is incompletely understood, various putative mechanisms are suggested. These may be of special importance in the advent of the newer monoclonal anti-CD20 antibodies. Recent findings: The incidence of LON varies with the clinical setting in which rituximab is administered. Administration of rituximab in the setting of stem cell transplantation significantly increases the risk for LON. The timing of rituximab administration after transplantation may affect the risk and severity of neutropenia. Recent data suggest that in rheumatologic diseases, the incidence of LON is comparable to that in the hematologic population. Suggested mechanisms for LON include humoral and cellular immune mechanisms as well processes that stem from B-cell recovery and its impact on neutrophil kinetics. Recently, an association between specific polymorphism in the immunoglobulin G Fc receptor FCgRIIIa 158 V/F and LON was demonstrated. Summary: LON is an increasingly recognized late adverse event of rituximab therapy. Acquaintance with the incidence, risk factors, natural history, and expected complications of LON may improve proper clinical management. Many aspects in the clinical management of LON remain to be answered during further studies aimed at this goal.

Original languageEnglish
Pages (from-to)32-38
Number of pages7
JournalCurrent Opinion in Hematology
Volume19
Issue number1
DOIs
StatePublished - 1 Jan 2012
Externally publishedYes

Keywords

  • Late-onset neutropenia
  • Neutropenia
  • Rituximab

Fingerprint

Dive into the research topics of 'Neutropenia after rituximab treatment: New insights on a late complication'. Together they form a unique fingerprint.

Cite this